Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284211 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BNOD1EPHX1ACHE | |
| SCHEMBL3655323 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BNOD1EPHX1ACHE | |
| SCHEMBL1077922 | 0.93 | NOD1 (0.48) | ITGB3ITGA2BNOD1EPHX1ACHE | |
| SCHEMBL7382637 | 0.93 | NOD1 (0.48) | ITGB3ITGA2BNOD1EPHX1ACHE | |
| SCHEMBL3625936 | 0.92 | NOD1 (0.50) | ITGB3ITGA2BNOD1EPHX1TGM2 | |
| SCHEMBL3629433 | 0.90 | NOD1 (0.53) | NOD1EPHX1ACHE | |
| SCHEMBL7447157 | 0.89 | FOLH1 (0.51) | ITGB3ITGA2BNOD1 | |
| SCHEMBL27864209 | 0.89 | ITGB3 (0.43) | ITGB3ITGA2BNOD1EPHX1ACHE | |
| SCHEMBL5513128 | 0.89 | ITGB3 (0.43) | ITGB3ITGA2BNOD1EPHX1CTSK | |
| SCHEMBL17175410 | 0.89 | NOD1 (0.45) | ITGB3ITGA2BNOD1EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1019046-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0353317-A1 | Tripeptides of N3-4-methoxyfumaryl-L-2,3-diaminopropanoic acid and the method of their obtaining | POLITECHNIKA GDANSKA (PL) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | ITGB3 1295/4885ITGA2B 1622/4885NOD1 1278/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | ITGB3 1512/4885ITGA2B 2085/4885NOD1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.